Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
Urinary hydroxyproline (HP) excretion has been estimated without prior dietary restriction in 33 patients with carcinoma of the prostate and expressed as either 24-h HP output or as the hydroxyproline/creatinine (HP/Cr) ratio in 24-h urine sample, an early morning urine sample or a spot urine sample. The early morning urine hydroxyproline/creatinine ratio (EMU HP/Cr) appears to be the most accurate and avoids the disadvantages of formal dietary restriction and prolonged urine collection. The rest is useful in monitoring the responses to treatment of a patient with bony metastatic disease and relapse of a patient when his tumour ceases to be hormone sensitive. Furthermore, changes in EMU HP/Cr occur earlier than changes in other clinical or investigative variables, giving the test predictive value.
D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D003404:Creatinine / Q000652:urine; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000652:urine*; D013048:Specimen Handling
D003404:Creatinine; D006909:Hydroxyproline